Sort   by:  
 Page size 
TranscriptomicsHuman TNBC Cells 48h Treatment with OTSSP167 MELK Inhibitor vs. DMSO Control
Microarray comparing TNBC cells treated for 48 hours with OTSSp167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 48h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-68652 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 45nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-68692 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-68691 | biostudies-arrayexpress
ProteomicsProteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein Targets
Treatment and relevant targets for breast cancer (BC) remain limited, especially for triple-negative BC (TNBC). We identified 6091 proteins of 76 human BC cell lines using data-independent acquisition (DIA). Integrating prior multi-omics datasets with our proteomic results, we found that including p...
ORGANISM(S): Homo Sapiens 
PXD043471 |
TranscriptomicsmicroRNA profiling of luminal and TNBC breast cancer cell lines
two luminal cell lines were added, MCF7 and BT-474 two TNBC cell line were added, MB231 and BT-549 microRNA expression profiles were conpared between the luminal group and the TNBC group
ORGANISM(S): Homo sapiens 
2014-10-03 | E-GEOD-62022 | biostudies-arrayexpress
GenomicsDNA methylation profiling of human triple negative breast cancer (TNBC) cell lines
DNA methylation profiling of human triple negative breast cancer (TNBC) cell lines
PRJNA1188174 | ENA
TranscriptomicsHuman TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159)
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: SUM159 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-71026 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159)
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: SUM159 cells were treated with either 45nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-71027 | biostudies-arrayexpress
GenomicsLigand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
Glucocorticoids (GC) have been widely used as coadjuvants in the treatment of solid tumors, but GC treatment may be associated with poor pharmacotherapeutic response and/or prognosis. The genomic action of GC in these tumors is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC) r...
ORGANISM(S): Homo sapiens 
2015-09-18 | E-GEOD-56022 | biostudies-arrayexpress
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
Sort   by:  
 Page size